NURO (NeuroMetrix) Debt-to-Revenue : 0.06 (As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

NeuroMetrix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.14 Mil. NeuroMetrix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. NeuroMetrix's annualized Revenue for the quarter that ended in Sep. 2024 was $2.35 Mil. NeuroMetrix's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.06.

NeuroMetrix Debt-to-Revenue Historical Data

The historical data trend for NeuroMetrix's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix Debt-to-Revenue Chart

NeuroMetrix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.16

0.14

0.07

0.04

NeuroMetrix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															0.06	0.05	0.05	0.06	0.06

Competitive Comparison of NeuroMetrix's Debt-to-Revenue

For the Medical Devices subindustry, NeuroMetrix's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroMetrix's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroMetrix's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where NeuroMetrix's Debt-to-Revenue falls into.

NeuroMetrix Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

NeuroMetrix's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.148	+	0.092)	/	5.901
	=	0.04

NeuroMetrix's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.143	+	0)	/	2.348
	=	0.06

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

NeuroMetrix Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroMetrix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

4B Gill Street, Woburn, MA, USA, 01801

Website

https://www.neurometrix.com

NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.

Executives

Bradley M Fluegel	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins	officer: Chief Financial Officer
Topline Capital Management, Llc	other: See Explanation in Footnotes	544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp	10 percent owner	544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin	other: See Explanation in Footnotes	544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani	director, officer: Chairman, President and CEO	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin	officer: Senior VP, Consumer	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van	director	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran	officer: S. VP and GM, International	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz	director	CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc	officer: Senior Vice President & GM
Walter Christensen	officer: Sr. VP, Global Sales	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor	director	100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C)	10 percent owner	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p.	10 percent owner	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017